Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure

Executive Summary

Termination of osteoporosis drug odanacatib due to stroke risk means a loss for Merck in reliving the glory days of branded Fosamax.

You may also be interested in...



Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C

The latest drug development news and highlights from our FDA Performance Tracker.

Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?

Abaloparatide looks better for improving bone mass with less hypercalcemia than Lilly's first-in-class Forteo in the Phase III ACTIVE study, but it remains to be seen whether this will be enough to get ahead in the increasingly crowded osteoporosis market.

Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck

Amgen Inc. and partner UCB Group have filed their osteoporosis drug romosozumab, which is anticipated to drive sales of more than $700m worldwide by 2023, in the US for the treatment of postmenopausal women at risk of fractures.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel